← Back to Search

Radiopharmaceutical

99mTc-Sestamibi for Coronary Artery Disease

Phase 2

Waitlist Available

Led By Gary Heller, MD

Research Sponsored by Cell>Point LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up visit 1a through visit 3 approximately 3 to 20 days

Awards & highlights

Study Summary

This trial will compare two different radiolabeled agents used to test for coronary artery disease during a rest and stress cardiac test.

Eligible Conditions

Coronary Artery Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ visit 1a through visit 3 approximately 3 to 20 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~visit 1a through visit 3 approximately 3 to 20 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and visit 1a through visit 3 approximately 3 to 20 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Efficacy: Characterization of the efficacy of 99mTCc-ECDG in the evaluation of Coronary Artery Disease

Secondary outcome measures

Safety: The number of participants with Adverse Events

Trial Design

1Treatment groups

Experimental Treatment

Group I: 99mTc-EC-DG, DiagnosticExperimental Treatment1 Intervention

99mTc-EC-DG (25 ± 5 mCi, up to 250 µg EC-DG) will be administered by intravenous (IV) bolus injection. Other Name:Technetium-99m-labeled Ethylenedicysteine-Deoxyglucose

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

99mTc-Sestamibi

2012

N/A

~120

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Cell>Point LLCLead Sponsor

4 Previous Clinical Trials

182 Total Patients Enrolled

1 Trials studying Coronary Artery Disease

2 Patients Enrolled for Coronary Artery Disease

Gary Heller, MDPrincipal InvestigatorConsultant

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does 99mTc-Sestamibi have any harmful side effects?

"While there is some clinical evidence supporting the safety of 99mTc-Sestamibi, it only received a score of 2 because this drug has not yet been proven effective."

Answered by AI

Are new patients being accepted into this clinical trial right now?

"As of now, this clinical trial has no more slots for patients. The first posting was on January 10th 2021 with the most recent update being 28 days later. Although 593 other trials are currently underway."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

2021. "Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01899833.

All > Coronary Artery Disease